Pear Therapeutics to go public in nearly $1.6bn SPAC deal
Pear’s three FDA-authorised PDTs serve several million patients with opioid use disorders and chronic insomnia.
News
Philips enrols first subject in iFR-guided PCI procedure study
The DEFINE GPS trial is a follow-up to a one-year DEFINE PCI study, which analysed...
Biocept and Quest Diagnostics partner on lung cancer biopsy test
The partnership will use Biocept's less invasive, lab-developed assay to conduct genomic profiling in advanced...
Thermo Fisher introduces new Covid-19 test for variant detection
The test can detect existing and emergent SARS-CoV-2 variants by using eight targets across three...
Computerised brain implant reduces pain in NYU Langone’s study
The brain implant is said to be the first of its kind that targets chronic...
Medtronic obtains expanded FDA approval for cryoablation catheters
The catheters are indicated for treating paroxysmal atrial fibrillation as an early rhythm control strategy.
India’s IISc creates diagnostic test for sickle-cell disease
The low-cost absorbance spectroscopy-based test could become an alternative to HPLC.
University of Chicago report details scope of healthcare algorithmic bias
The report contains a plan of action healthcare companies can take to avoid algorithmic bias going forward.
Co-Diagnostics obtains CE mark for SARS-CoV-2 saliva test
The test eliminates the need for RNA extraction from the samples, an expensive and time-consuming process.
FDA grants EUA to Roche’s 20-minute Covid-19 PCR test
The test can be used for symptomatic or asymptomatic people and delivers results in 20 minutes.
Cala Health and UCSF to develop neuromodulation therapies
The technologies licenced from UCSF will boost Cala Health’s pipeline of neurology treatments.
